Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Y9TS
|
|||
Former ID |
DAP000961
|
|||
Drug Name |
Ceruletide
|
|||
Synonyms |
Caerulein; Cerulein; Ceruletida; Ceruletidum; Ceruletida [INN-Spanish]; Ceruletidum [INN-Latin]; Ceruletide (USAN/INN); Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Caerulein stimulated gastric and pancreatic secretion [ICD-11: 5A4Y] | Approved | [1] | |
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 3 | [2], [3] | ||
Therapeutic Class |
Diagnostic Agents
|
|||
Company |
Pharmacia And Upjohn Co
|
|||
Structure |
Download2D MOL |
|||
Formula |
C58H73N13O21S2
|
|||
Canonical SMILES |
CC(C(C(=O)NCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N)NC(=O)C(CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C5CCC(=O)N5)O
|
|||
InChI |
1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1
|
|||
InChIKey |
YRALAIOMGQZKOW-HYAOXDFASA-N
|
|||
CAS Number |
CAS 17650-98-5
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:59219
|
|||
SuperDrug ATC ID |
V04CC04
|
|||
SuperDrug CAS ID |
cas=017650985
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Gastrin/cholecystokinin type B receptor (CCKBR) | Target Info | Agonist | [4] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Gastric acid secretion | ||||
Panther Pathway | CCKR signaling map ST | |||
Pathwhiz Pathway | Gastric Acid Production | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Secretion of Hydrochloric Acid in Parietal Cells | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7589). | |||
REF 3 | Inhibitory effect of CCK-8 and ceruletide on glutamate-induced rises in intracellular free calcium concentrations in rat neuron cultures. Brain Res. 1992 Aug 21;588(2):223-8. | |||
REF 4 | Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.